At a Glance
Lupin Ltd, the Mumbai-based pharma juggernaut, flexed its muscles this quarter like it just downed a protein shake. Q1 FY26 revenue jumped 11.8% YoY to ₹6,268 crore, while PAT rocketed 51.6% to ₹1,221 crore, thanks to a cocktail of strong US sales, two ANDA approvals, and expanded margins at a fat 28% OPM. The stock, at ₹1,847, trades at a P/E of 22.9x—not dirt cheap but not nosebleed either for a company with 63% profit growth TTM. Cue applause, or skepticism, depending on how much you love pharma volatility.
Introduction
In pharma land, where US FDA inspections give CEOs nightmares and generics pricing can swing faster than Elon Musk’s tweets, Lupin is quietly pulling off a comeback. After years of flatlining sales, the company is now flexing its innovation-led strategy, beefing up its US portfolio and delivering blockbuster earnings.
But investors have been here before—Lupin shines one quarter, stumbles the next. So is Q1 FY26 a genuine steroid shot for sustained growth or just a sugar rush?
Business Model (WTF Do They Even Do?)
Lupin is the Swiss Army knife of pharma:
- Generics: Bread and butter, with a strong foothold in US, India, and Europe.
- Biotech Products: High-margin segment, still ramping up.
- APIs: Critical raw materials, also exported.
- Therapeutic Leadership: Cardiovascular, diabetes, asthma, CNS, anti-TB, and cephalosporins—basically, if you’re sick, they’ve got something.
The company operates in over 100 countries, making it one of India’s truly global pharma names.
Financials Overview
Q1 FY26 Snapshot
- Revenue: ₹6,268 crore (+11.8% YoY)
- EBITDA: ₹1,727 crore (OPM 28%)
- PAT: ₹1,221 crore (+51.6% YoY)
- EPS: ₹26.7
FY25 Recap
- Revenue ₹22,708 crore (+13% YoY)
- PAT ₹3,306 crore (+70% YoY)
- ROE 20.6%, ROCE 21.3%
- Debt ₹5,448 crore (manageable at <0.3x D/E)
💡 Commentary: Operating margins have expanded like they’re on growth hormones—up from
